The purpose of this study is to compare the effects, good and/or bad, of abiraterone, prednisone, and enzalutamide with enzalutamide alone on patients that have prostate cancer that has spread and has not responded to hormonal therapy to find out which is better.
Doctors are uncertain about what is the best way to treat castration resistant prostate cancer (CRPC). In this study, patients will get either the combination of abiraterone, prednisone, and enzalutamide or enzalutamide alone.
Abiraterone and enzalutamide are both hormonal agents approved by the Food and Drug Administration for patients with castration-resistant metastatic disease. Each drug works in a different way to block hormones. Abiraterone and enzalutamide are both highly effective drugs in blocking hormones in men with CRPC. Abiraterone has recently received FDA approval for patients who have not received chemotherapy, such those patients eligible for this study.
Click here for more information from the National Cancer Institute.